AIP.	<u>E7</u>			· · · · · · · · · · · · · · · · · · ·				
MAY 2 6 2	004 ×		. Atty. Docket No.: 7570/80968	Appl. No.: 10/772,089				
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			Applicant(s) Farzan, et al.					
TRADE			Filing Date: February 5, 2004	Group: to be assigned				
Examiner Initial	_	OTHER PRIOR ART (Inclu	ding Author, Title, Date, Pertinent Pages, Etc.)	• •				
A	C I	BERGER, "HIV Entry and Tropism: The C	hemokine Receptor Connection," AIDS 11(S	upp. A):S3-S16 (1997).				
	C 2		eation Epitopes of Simian Immunodeficiency m Monkeys Infected with an Attenuated SIV					
	C 3	CORMIER, et al., "Specific Interaction of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines with HIV-1 Envelope Glycoprotein gp120," Proc. Natl. Acad. Sci. USA 97:5762-5767 (2000).						
	C 4	DENG, et al., "Identification of a Major Co	-Receptor for Primary Isolates of HIV-1," No	ature 381:661-666 (1996).				
	C 5	DORANZ, et al., "Chemokine Receptors as Immunologic Research 16:15-28 (1997).	DORANZ, et al., "Chemokine Receptors as Fusion Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1)," Immunologic Research 16:15-28 (1997).					
	C 6	DRAGIC, et al., "HIV-1 Entry. into CDR+ C 381:667-673 (1996).	Cells Is Mediated by the Chemokine Receptor	CC-CKR-5," Nature .				
	C 7	FARZAN, et al., "A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5," J. Virol. 72:1160-1164 (1998).						
	C 8	FARZAN, et al., "Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry," Cell 96:667-676 (1999).						
	С9	FARZAN, et al., "A Tyrosine-Sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-Enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry," J. Biol. Chem. 275:33516-33521 (2000).						
	C 10	FOUTS, et al., "Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex," J. Virol. 71:2779-2785 (1997).						
4	C _. 11	HO, et al., "Conformational Epitope on gp120 Important in CD4 Binding and Human Immunodeficiency Virus Type I Neutralization Identified by a Human Monoclonal Antibody," J. Virol. 65:489-493 (1991).						
	C 12							
	C 13							
	C 14							
	C 15							
	C 16							
	C 17							
	C 18							
Examiner	2		Date Considered 06/25/07					

FETF 1449 5/03

10/772,089 Application Number PTO/SB/08a Substitute for Form 1449A/PTG February 5, 2004 Filing Date FARZAN et al. INFORMATION DISCLOSURE First Named Inventor STATEMENT BY APPLICANT 1614 1648 Art Unit IBA PARKEN ORPENSEY (Use as many sheets as necessary) Examiner Name 7570/80968 **Attorney Docket** 2 of Sheet

			U.S. PATENT D	OCUMENTS	Pages, Columns, Lines,
	Cite No.1	Document Number	Publication Data	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ²	MM-DD-YYYY		
		US-2002/0068813 A1	06-06-2002	DRAGIC et al.	
bo		US-2001/0039026 A1	11-08-2001	DOBBS et al.	
		US-			
	A4	US-			-
	A5	US-			
		US-	 		
		US-			
		US		<u> </u>	
		US-			
	1.	US-			
		US-			

		FOREI	GN PATENT D	OCOMENTS	Pages, Columns, Lines,	ì
	0:22	Foreign Patent Document	Publication Date	Name of Patentee or	Where Relevant Passages or Relevant Figures Appear	Τ,
Examiner Initials*	Cite No.'	Country Code ³ -Number ⁴ -Kind Code ⁵	MM-DD-YYYY	Applicant of Cited Document	Of Holdren	T
	В1					
	B2					\prod
	вз		 		·	
	В4		 			1
	B5		 			1
	-		 			\downarrow
	-		 			\downarrow
L						┙

Date Examiner Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Capplicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Capplicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Applicant s unique citation designation number toptional). The Nind Codes of OFFIC Fatent Documents at www.uspio.gov of MFEF 301.04.

The Policant s unique citation designation number toptional). The Nind Codes of OFFIC Fatent Documents at www.uspio.gov of MFEF 301.04.

The Policant s unique citation designation number toptionally. The Nind Codes of OFFIC Fatent Documents at www.uspio.gov of MFEF 301.04.

The Policant s unique citation designation number toptionally. The Nind Codes of OFFIC Fatent Documents at www.uspio.gov of MFEF 301.04.

The Policant s unique citation designation number toptionally. The Nind Codes of OFFIC Fatent Documents at www.uspio.gov of MFEF 301.04.

The Policant s unique citation designation number toptionally. The Nind Codes of OFFIC Fatent Documents at www.uspio.gov of the English language Translation indicated on the document under WIPO Standard ST.16 if possible. The Policant is to place a check mark here if English language Translation indicated on the document under WIPO Standard ST.16 if possible. The Policant is to place a check mark here if English language Translation indicated on the document under WIPO Standard ST.16 if possible. is attached.

PTO/SB/08b Substitute for Form 1449B/PTO				Application Number	10/772.089		
				Filing Date	February 5, 2004		
INFO	RMATION	N DISC	LOSURE	First Named Inventor	FARZAN et al.		
STATEMENT BY APPLICANT			PLICANT	Art Unit	1614 648		
(Use as many sheets as necessary)				Examiner Name	IBA PARKEN, OBSTRONT		
Sheet	2	of	2	Attorney Docket	7570/80968		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
7	C 1	FARZAN, M.; A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 interacts with a CD4- enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry.; October 27, 2000, Vol. 275, No. 43, pages 33516-33521.					
	C2						
	СЗ						
	C4						
	C5	·					
Examiner Signature		Date Considered 04 25 07					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.